IRIS
TRIVELLIN, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 331
AS - Asia 244
EU - Europa 189
AF - Africa 4
SA - Sud America 1
Totale 769
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 311
CN - Cina 121
SG - Singapore 109
IE - Irlanda 56
FI - Finlandia 55
DE - Germania 18
CA - Canada 17
GB - Regno Unito 16
RU - Federazione Russa 13
CZ - Repubblica Ceca 12
IT - Italia 7
JP - Giappone 6
PK - Pakistan 6
FR - Francia 4
CH - Svizzera 3
MX - Messico 3
SE - Svezia 3
NG - Nigeria 2
ZA - Sudafrica 2
BE - Belgio 1
BR - Brasile 1
IL - Israele 1
IN - India 1
NL - Olanda 1
Totale 769
Salva come PNG Salva come JPEG
Città #
Shanghai 120
Boardman 80
Singapore 69
Dublin 56
New York 56
Helsinki 55
Los Angeles 19
Gatineau 16
Phoenix 14
Moscow 13
Seattle 13
Brno 12
Chandler 8
Santa Clara 8
Lahore 6
Houston 5
Southwark 5
Higashiosaka 4
Monterrey 3
Munich 3
Nashville 3
Soissons 3
Benin City 2
Bristol 2
Geneva 2
Johannesburg 2
Lawrence 2
Manchester 2
Milan 2
Osaka 2
Princeton 2
Stockholm 2
Turi 2
Atlanta 1
Buffalo 1
Cambridge 1
Carrollton 1
Chicago 1
Falkenstein 1
Hangzhou 1
Heimberg 1
Hounslow 1
Jamaica Plain 1
Jerusalem 1
Leiden 1
Liège 1
London 1
Paris 1
Pune 1
San Francisco 1
San Mateo 1
Santo André 1
Tenhult 1
Woodford Green 1
Totale 614
Salva come PNG Salva come JPEG
Nome #
Use of G protein-coupled receptor 101 inhibitor, antagonist or inverse agonist for prevention and/or therapeutic treatment of diseases selected from group consisting of acromegaly and gigantism 65
Case Report: New CDKN1B Mutation in Multiple Endocrine Neoplasia Type 4 and Brief Literature Review on Clinical Management 35
Characterization of GPR101: Transcripts Structure, Expression Pattern, and Signal Transduction Pathways 31
X-Linked Acro-Gigantism (X-LAG) Due to Microduplications of Chromosome Xq26: A New Disorder and Implications for Acromegaly 24
Alteration of the immunophenotype and cytokine profiles in patients affected by neuroendocrine neoplasms 22
Characterization of GPR101 Expression Across Different Species 18
CD40LG duplications in patients with X-LAG syndrome commonly undergo random X-chromosome inactivation 15
Chaperones, somatotroph tumors and the cyclic AMP (cAMP)-dependent protein kinase (PKA) pathway 15
AIP Mutation in Pituitary Adenomas REPLY 15
X-linked acro-gigantism (X-LAG): a new form of infant-onset pituitary gigantism 15
A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers 14
Increased expression of miR-34a explains the low AIP protein level present in 50% of sporadic somatotropinomas 14
AIP and its interacting partners 14
Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome 14
Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up 14
Xq26.3 Duplication in a Boy With Motor Delay and Low Muscle Tone Refines the X-Linked Acrogigantism Genetic Locus 13
Characterization of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutations in Familial Isolated Pituitary Adenoma Families 13
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors 13
A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred 13
Characterization of the adiponectin promoter + Cre recombinase insertion in the Tg(Adipoq-cre)1Evdr mouse by targeted locus amplification and droplet digital PCR 13
Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients 12
Evaluation of CDKN1B germline mutations in a cohort of acromegalic patients with evidences of multiple neoplasia 12
An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations 12
The direct impact of pegvisomant on osteoblast functions and bone development 11
Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly? 11
MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro 11
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 11
Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway 10
Stable GPR101 over-expressing cell lines as an invaluable tool for functional studies, ligand screening, and the identification of deregulated genes/pathways in patients with X-linked acrogigantism 10
Evaluation of mutations in aryl hydrocarbon receptor interacting protein (AIP) in acromegalic sporadic cases and in one FIPA family 10
Characterization of GPR101 transcript structure and expression patterns 10
Evaluation of p27KIP1 germline mutations in familial phaeochromocytoma and clinically suspected MEN1 patients 10
miR-107 inhibits the expression of aryl hydrocarbon receptor interacting protein (AIP) and is potentially involved in pituitary tumorigenesis 9
Familial pituitary apoplexy as the only presentation of a novel AIP mutation 9
Macronodular Adrenal Hyperplasia due to Mutations in an Armadillo Repeat Containing 5 (ARMC5) Gene: A Clinical and Genetic Investigation 9
Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations 9
The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect? 9
Diagnosis and Treatment of Parasellar Lesions 9
MicroRNAs: Suggested role in pituitary adenoma pathogenesis 9
Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia 9
SATB1: a gene involved in pituitary development may have a role in somatotroph tumors 9
Cyclic 3',5'-adenosine monophosphate (cAMP) signaling in the anterior pituitary gland in health and disease 9
The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors 9
GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency 8
Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants 8
A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype 8
Familial isolated pituitary adenomas: An emerging clinical entity 8
Hereditary endocrine tumours: Current state-of-the-art and research opportunities: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA) 8
Is IGSF1 involved in human pituitary tumor formation? 8
FAF1 Gene Involvement in Pituitary Corticotroph Tumors 8
Oncogene-induced senescence in pituitary adenomas and carcinomas 7
Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation 7
Interaction of AIP with protein kinase A (cAMP-dependent protein kinase) 7
Prkar1a haploinsufficiency ameliorates the growth hormone excess phenotype in Aip-deficient mice 7
Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers 7
Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess 7
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study 7
Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism 7
Genetics of gigantism and acromegaly 7
Hereditary endocrine tumours: Current state-of-the-art and research opportunities: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis 6
Filamin A is involved in human intrahepatic cholangiocarcinoma aggressiveness and progression 6
MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics 6
Pituitary gigantism: update on molecular biology and management 6
Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas 6
The Glucose-Dependent Insulinotropic Polypeptide Receptor is Overexpressed Amongst GNAS1 Mutation-Negative Somatotropinomas and Drives Growth Hormone (GH)-Promoter Activity in GH3 Cells 6
The X-linked acrogigantism-associated gene gpr101 is a regulator of early embryonic development and growth in zebrafish 6
Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's disease 6
Gigantism, Acromegaly, and GPR101 Mutations REPLY 6
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion 6
IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction 6
PAM variants in patients with thyrotrophinomas, cyclical Cushing's disease and prolactinomas 6
Large genomic aberrations in corticotropinomas are associated with greater aggressiveness 6
Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal alpha-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition 6
GPR101: Modeling a constitutively active receptor linked to X-linked acrogigantism 5
Screening for GPR101 defects in pediatric pituitary corticotropinomas 5
Genetics, clinical features and outcomes of non-syndromic pituitary gigantism: experience of a single center from Sao Paulo, Brazil 5
GHRH excess and blockade in X-LAG syndrome 5
Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland 5
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects 4
Totale 851
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.293
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.293
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202210 0 0 0 0 0 0 0 0 1 4 4 1
2022/202396 4 2 2 2 3 2 0 1 6 4 0 70
2023/2024706 50 31 145 21 36 80 90 50 13 24 61 105
2024/202539 37 2 0 0 0 0 0 0 0 0 0 0
Totale 851